Such co-culture model systems for autologous HBVs+ HCC organoids and CD39+ HBV-CAR-T cells or CD39+ personalized tumor-reactive CD8+ T cells were also modeled to assess their anticancer efficiency (75). This evidence concerns the gene CD8A and neoplasm.